{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:39:48Z","timestamp":1784075988625,"version":"3.55.0"},"reference-count":41,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cystic fibrosis (CF) is characterized by a progressive decline in lung function, which may be further impaired by viral infections. CF is therefore considered a comorbidity of coronavirus disease 2019 (COVID-19), and SARS-CoV-2 vaccine prioritization has been proposed for patients with (pw)CF. Poor outcomes have been reported in lung transplant recipients (LTR) after SARS-CoV-2 infections. LTR have also displayed poor immunization against SARS-CoV-2 after mRNA-based BNT162b2 vaccination, especially in those undergoing immunosuppressive treatment, mostly those receiving mycophenolate mofetil (MMF) therapy. We aimed to determine here the immunogenicity and safety of the BNT162b2 vaccine in our cohort of 260 pwCF, including 18 LTR. Serum levels of neutralizing anti-SARS-CoV-2 IgG and IgA antibodies were quantified after the administration of two doses. PwCF displayed a vaccine-induced IgG and IgA antiviral response comparable with that seen in the general population. We also observed that the immunogenicity of the BNT162b2 vaccine was significantly impaired in the LTR subcohort, especially in patients undergoing MMF therapy. The BNT162b2 vaccine also caused minor adverse events as in the general population, mostly after administration of the second dose. Overall, our results justify the use of the BNT162b2 vaccine in pwCF and highlight the importance of a longitudinal assessment of the anti-SARS-CoV-2 IgG and IgA neutralizing antibody response to COVID-19 vaccination.<\/jats:p>","DOI":"10.3390\/ijms24020908","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T05:02:30Z","timestamp":1672808550000},"page":"908","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation"],"prefix":"10.3390","volume":"24","author":[{"given":"Francesca","family":"Lucca","sequence":"first","affiliation":[{"name":"Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata di Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6849-4487","authenticated-orcid":false,"given":"Valentino","family":"Bezzerri","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata di Verona, 37126 Verona, Italy"},{"name":"Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2454-0410","authenticated-orcid":false,"given":"Elisa","family":"Danese","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-0364","authenticated-orcid":false,"given":"Debora","family":"Olioso","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Peserico","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9982-4100","authenticated-orcid":false,"given":"Christian","family":"Boni","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata di Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cucchetto","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata di Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8999-0001","authenticated-orcid":false,"given":"Martina","family":"Montagnana","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Tridello","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata di Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Meneghelli","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata di Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8786-4615","authenticated-orcid":false,"given":"Mirco","family":"Ros","sequence":"additional","affiliation":[{"name":"Unit of Pediatrics, S. Maria di Ca\u2019 Foncello Hospital, 31100 Treviso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-9054","authenticated-orcid":false,"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cipolli","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata di Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Chen, Y., Zhao, X., Zhou, H., Zhu, H., Jiang, S., and Wang, P. (2022). Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol.","DOI":"10.1038\/s41577-022-00784-3"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S2666-5247(21)00266-4","article-title":"WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: Call for urgent action by the scientific community","volume":"3","author":"Knezevic","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Colombo, C., Alicandro, G., Dacc\u00f3, V., Gagliano, V., Morlacchi, L.C., Casciaro, R., Pisi, G., Francalanci, M., Badolato, R., and Bignamini, E. (2021). SARS-CoV-2 infection in cystic fibrosis: A multicentre prospective study with a control group, Italy, February-July 2020. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0251527"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Corvol, H., de Miranda, S., Lemonnier, L., Kemgang, A., Reynaud Gaubert, M., Chiron, R., Dalphin, M.L., Durieu, I., Dubus, J.C., and Houdouin, V. (2020). First Wave of COVID-19 in French Patients with Cystic Fibrosis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113624"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jcf.2020.04.012","article-title":"A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis","volume":"19","author":"Cosgriff","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"00411","DOI":"10.1183\/23120541.00411-2021","article-title":"Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe","volume":"7","author":"Jung","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s15010-021-01737-z","article-title":"Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: A study within the Italian Cystic Fibrosis Society","volume":"50","author":"Colombo","year":"2021","journal-title":"Infection"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jcf.2021.03.028","article-title":"COVID-19 vaccine prioritisation for people with cystic fibrosis","volume":"20","author":"Carr","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines","volume":"385","author":"Thompson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMoa2200797","article-title":"Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar","volume":"386","author":"Chemaitelly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.healun.2021.08.010","article-title":"Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience","volume":"41","author":"Peled","year":"2022","journal-title":"J. Heart Lung Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"eabj1031","DOI":"10.1126\/sciimmunol.abj1031","article-title":"Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients","volume":"6","author":"Choi","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e150175","DOI":"10.1172\/JCI150175","article-title":"Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients","volume":"131","author":"Sattler","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Narasimhan, M., Mahimainathan, L., Clark, A.E., Usmani, A., Cao, J., Araj, E., Torres, F., Sarode, R., Kaza, V., and Lacelle, C. (2021). Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. Vaccines, 9.","DOI":"10.1101\/2021.04.26.21255926"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1002\/jmv.27044","article-title":"Lack of immune response after mRNA vaccination to SARS-CoV-2 in a solid organ transplant patient","volume":"93","author":"Rusk","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e13628","DOI":"10.1111\/tid.13628","article-title":"SARS-CoV-2 infection after two doses of mRNA vaccine in renal transplant recipients","volume":"23","author":"Ivo","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Alicandro, G., Dacc\u00f2, V., Cariani, L., Rosazza, C., Sciarrabba, C.S., Ferraro, F., Lanfranchi, C., Medino, P., Girelli, D., and Colombo, C. (2022). Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies. Biomedicines, 10.","DOI":"10.20944\/preprints202207.0422.v1"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/j.jcf.2022.04.004","article-title":"Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis","volume":"21","author":"Michos","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1002\/jmv.27058","article-title":"SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection","volume":"93","author":"Zervou","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.5937\/jomb0-32373","article-title":"Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers","volume":"40","author":"Salvagno","year":"2021","journal-title":"J. Med. Biochem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/22221751.2021.1953403","article-title":"Antibody titres decline 3-month post-vaccination with BNT162b2","volume":"10","author":"Favresse","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1093\/cid\/ciac470","article-title":"Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021","volume":"75","author":"Busch","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1002\/jmv.26982","article-title":"Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection","volume":"93","author":"Callegaro","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bezzerri, V., Gentili, V., Api, M., Finotti, A., Papi, C., Tamanini, A., Olioso, D., Duca, M., Tedesco, E., and Leo, S. ACE2 expression and localization are regulated by CFTR: Implications beyond cystic fibrosis. bioRxiv, 2021.","DOI":"10.1101\/2021.11.19.469220"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1080\/22221751.2021.2004866","article-title":"SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response","volume":"10","author":"Mileto","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1016\/S2665-9913(22)00066-2","article-title":"Humoral response following SARS-CoV-2 vaccination: Not all immunosuppressants are created equal","volume":"4","author":"Connolly","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.healun.2021.05.004","article-title":"Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients","volume":"40","author":"Havlin","year":"2021","journal-title":"J. Heart Lung. Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.7326\/M21-1341","article-title":"Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants","volume":"174","author":"Marion","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.kint.2021.05.011","article-title":"Occurrence of severe COVID-19 in vaccinated transplant patients","volume":"100","author":"Caillard","year":"2021","journal-title":"Kidney Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A Bivalent Omicron-Containing Booster Vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1515\/cclm-2021-0972","article-title":"Optimizing effectiveness of COVID-19 vaccination: Will laboratory stewardship play a role?","volume":"59","author":"Lippi","year":"2021","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/908\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:58:15Z","timestamp":1760119095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24020908"],"URL":"https:\/\/doi.org\/10.3390\/ijms24020908","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]}}}